Graybug Vision, Inc. announced the appointment of three new members to the company’s Board of Directors with immediate effect. Christina Ackermann will chair Graybug’s Nominating and Corporate Governance Committee and serve as a member of its Compensation Committee. Eric Bjerkholt, MBA, will chair the company’s Compensation Committee and serve as a member of the Audit Committee. Julie Eastland, MBA, will chair the Audit Committee. Ms. Ackermann, Mr. Bjerkholt and Ms. Eastland replace Emmett Cunningham, Jr., MD, PhD, Managing Director at Blackstone Lifesciences Group, Chau Q. Khuong, MPH, Partner at OrbiMed, and Cameron Wheeler, PhD, Partner at Deerfield, all of whom served on Graybug’s Board of Directors representing three of Graybug’s long-term private investors. Christina Ackermann currently serves as Executive Vice President, General Counsel and Head of Commercial Operations at Bausch Health Companies, Inc. Eric Bjerkholt currently is the Chief Financial Officer of Aimmune Therapeutics, Inc. Prior to joining Aimmune, Mr. Bjerkholt served as CFO at Sunesis Pharmaceuticals, Inc. Julie Eastland, Prior to joining Graybug’s Board of Directors, she served as Chief Financial Officer and Chief Business Officer of Rainier Therapeutics.